文献速递咽喉与嗓音

表演者短期口服糖皮质激素治疗声带水肿的安全性前瞻性评估

Prospective Evaluation of Safety of Singing on Steroids: Testing the Truth of Received Wisdom.
PubMed 文献 · Laryngoscope · 2021-02-19

结果显示声带出血发生率3.6%、声门鹅口疮5.5%,均为短暂性且无后遗症;黏膜波和水肿改善,EASE评分显著提高,多数表演者完成既定演出。结论认为口服糖皮质激素对急性声带水肿表演者总体安全,但用药前应强制进行声带检查。

要点

  • 短期口服糖皮质激素治疗急性声带水肿后,声带出血和鹅口疮发生率低且短暂。
  • 治疗后可观察到黏膜波动力学和水肿改善,EASE评分显著提高。
  • 给职业表演者处方糖皮质激素前,应强制进行声带检查。

核心结论

  • 口服糖皮质激素对表现为急性声带水肿的表演者总体安全,不良反应发生率低且短暂。
  • 包含糖皮质激素的急性声带水肿治疗策略可显著改善声门功能指标。

主要发现

  • 治疗后观察到2例声带出血(3.6%)和3例声门鹅口疮(5.5%),均无后遗症地消退。
  • 黏膜波动力学和水肿改善,几乎所有受试者完成既定演出,EASE评分显著改善。
  • CAPE-V及部分声学和空气动力学结果(女性半音音域、男性气流指标)有统计学显著改善。

关键数值与推荐

  • 声带出血发生率为3.6%(2例),声门鹅口疮发生率为5.5%(3例)。
  • 证据等级为4级。

临床怎么用

  • 对于急性声带水肿的表演者,可考虑使用短期口服糖皮质激素,但处方前应强制进行声带检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: Performing while on steroids is widely considered to increase risk of vocal injury. This study aims to determine incidence and type of injury, and changes in performers' voices after treatment of vocal fold edema (VFE) with glucocorticoids. STUDY DESIGN: Prospective Cohort. METHODS: Fifty-five performers (34 female; 21 male) treated for acute VFE with short-course oral glucocorticoids were prospectively evaluated pre- and post-treatment. Subjects underwent videostroboscopy, acoustic/aerodynamic assessment, and functional assessment with the Singing Voice Handicap Index-10 (SVHI-10) and Evaluation of the Ability to Sing Easily (EASE). Blinded reviewers rated videostroboscopic examinations and performed audio-perceptual assessment. Chi-square tests and Wilcoxon signed rank tests were applied for analyses of treatment changes. RESULTS: Following glucocorticoid treatment, two instances of vocal fold hemorrhage (3.6%) and three instances of glottic thrush (5.5%) were observed. These resolved without consequence. Mucosal wave dynamics and edema improved. Nearly all subjects completed scheduled performances, and significant improvement was noted on the EASE, reflecting improved function after treatment. These were further supported by statistically significant improvements in CAPE-V and some acoustic and aerodynamic outcomes (semitone pitch range for females, airflow measures for males). CONCLUSIONS: Oral glucocorticoids appear to be generally safe for performers presenting with acute VFE. The incidence of adverse effects, specifically hemorrhage and thrush, was low and the effects transient. Vocal fold examination should be considered obligatory before prescribing glucorticoids to working performers. A treatment strategy for acute VF edema incorporating glucocorticoids when appropriate appears to result in significant improvements in measures of glottal function including videostroboscopic appearance, subject perception, and auditory perception. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:2298-2304, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Murphy Estes C, Chadwick K, Sadoughi B, et al. Prospective Evaluation of Safety of Singing on Steroids: Testing the Truth of Received Wisdom. Laryngoscope. 2021. PMID: 33605442. doi:10.1002/lary.29437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。